Scholarlink

Background/Objectives <p>Glucagon-like peptide-1 receptor agonist medications (GLP-1s) are effective for weight loss, but when people discontinue them, they tend to regain weight. The present work sought to examine the stigma of losing and regaining weight after GLP-1 use and cessation.</p> Subjects/Methods <p>In two randomized, between-subjects experiments, participants evaluated a fictional target after reading a brief description of the target’s weight-related history, which varied by study condition. Study 1 (<i>N</i> = 607) aimed to understand stigma directed at individuals who lose weight using GLP-1s, so the target was described as either: having lost weight by using a GLP-1, having lost weight via diet and exercise, or not having lost weight. Study 2 (<i>N</i> = 706) examined stigma directed at people who regain weight after discontinuing GLP-1s, and the target was described as either: having regained weight after discontinuing a GLP-1, having regained weight after discontinuing a diet and exercise plan, not having lost weight, or having maintained weight loss. After reading, participants completed measures of weight-related stereotyping and willingness to affiliate with the target.</p> Results <p>In Study 1, the GLP-1 target was evaluated more negatively than the diet/exercise target and the no weight loss target. Participants’ willingness to affiliate differed significantly across groups (<i>p</i> &lt; 0.001), with the GLP-1 target receiving significantly lower ratings compared to the diet/exercise target (Mean difference = 0.52, 95% CI [0.27, 0.76]) and the no weight loss target (Mean difference = 0.26, 95% CI [0.02, 0.51]). In Study 2, the GLP-1 and diet/exercise targets were evaluated similarly, and both were rated more negatively than the target who maintained weight loss (<i>p</i>s ≤ 0.001).</p> Conclusions <p>These findings suggest that people may face stigma across the cycle of losing and regaining weight after using a GLP-1, underscoring the need for stigma-reduction efforts in the context of weight management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月3日

查看全文
  • Erin C. Standen,
  • Sean M. Phelan,
  • A. Janet Tomiyama

摘要

Background/Objectives

Glucagon-like peptide-1 receptor agonist medications (GLP-1s) are effective for weight loss, but when people discontinue them, they tend to regain weight. The present work sought to examine the stigma of losing and regaining weight after GLP-1 use and cessation.

Subjects/Methods

In two randomized, between-subjects experiments, participants evaluated a fictional target after reading a brief description of the target’s weight-related history, which varied by study condition. Study 1 (N = 607) aimed to understand stigma directed at individuals who lose weight using GLP-1s, so the target was described as either: having lost weight by using a GLP-1, having lost weight via diet and exercise, or not having lost weight. Study 2 (N = 706) examined stigma directed at people who regain weight after discontinuing GLP-1s, and the target was described as either: having regained weight after discontinuing a GLP-1, having regained weight after discontinuing a diet and exercise plan, not having lost weight, or having maintained weight loss. After reading, participants completed measures of weight-related stereotyping and willingness to affiliate with the target.

Results

In Study 1, the GLP-1 target was evaluated more negatively than the diet/exercise target and the no weight loss target. Participants’ willingness to affiliate differed significantly across groups (p < 0.001), with the GLP-1 target receiving significantly lower ratings compared to the diet/exercise target (Mean difference = 0.52, 95% CI [0.27, 0.76]) and the no weight loss target (Mean difference = 0.26, 95% CI [0.02, 0.51]). In Study 2, the GLP-1 and diet/exercise targets were evaluated similarly, and both were rated more negatively than the target who maintained weight loss (ps ≤ 0.001).

Conclusions

These findings suggest that people may face stigma across the cycle of losing and regaining weight after using a GLP-1, underscoring the need for stigma-reduction efforts in the context of weight management.